Physician profile
Matthew Alias
NPI 1730703372
$1,616.84
in general payments reported to CMS, 2019-2025
22 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2022: $42.88 · 2023: $77.60 · 2024: $259 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.81 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $268.68 | 2024-2025 | Tremfya, Stelara |
| Laborie Medical Technologies Corp. | $179.75 | 2025 | |
| Abbvie INC. | $169.67 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $163.25 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $148.91 | 2025 | Tremfya |
| Argenx US, INC. | $127.43 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $109.87 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Mallinckrodt Hospital Products INC. | $52.42 | 2025 | Terlivaz |
| Genzyme Corporation | $51.56 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.44 | 2024-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $38.47 | 2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $35.26 | 2024-2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $34.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2022 | |
| Medtronic, INC. | $24.80 | 2025 | Endoflip |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.54 | 2025 | Wegovy |
| Biocon Biologics INC | $23.08 | 2025 | Yesintek |
| Capsovision, INC. | $22.67 | 2024 | Capsocam Plus |
| Pfizer INC. | $19.87 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.24 | 2023 | Austedo |
| Boston Scientific Corporation | $13.99 | 2023 | |
| Jazz Pharmaceuticals INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Alias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.